Format

Send to

Choose Destination
Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Author information

1
CHRU Lille, Pôle Spécialités Médicales et Gérontologie (Medical Specialities and Gerontology), Service des Maladies du Sang (Department of Haematology), Secteur Allogreffe de Cellules Souches Hématopoïétiques (Allogeneic Stem Cell Transplantation Department), F59037, Lille, France.
2
Université de Lille (Lille University), UFR Médecine F59000, Lille, France.
3
Section of Haematology, Clinique Universitaire de St-Luc, Brussels, Belgium.
4
Department of Haematology, Caen University Hospital, Caen, France.
5
Department of Haematology, Henri-Mondor hospital, APHP, Paris, France.
6
Department of Haematology, Nantes University Hospital, Nantes, France.
7
Haematology Service, Oncology Department, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.
8
Department of Haematology, Pitié Salpêtrière Hospital, APHP, Paris, France.
9
Department of Haematology and Cellular Therapy, University Hospital Bordeaux, Bordeaux, France.
10
Department of Haematology, Grenoble University Hospital, Grenoble, France.
11
Department of Haematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
12
Bone Marrow Transplant Department, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
13
Department of Haematology, Nice University Hospital, Nice, France.
14
Department of Haematology, Toulouse University Hospital, Toulouse, France.
15
Department of Haematology, Angers University Hospital, Angers, France.
16
Department of Haematology, Rennes University Hospital, Rennes, France.
17
Department of Haematology, Percy Hospital, Clamart, France.
18
Haematological Early Drug Development Department, Gustave Roussy Institute, Paris, France.
19
Department of Haematology, Lyon University Hospital, Lyon, France.
20
Haematology and Pediatric Oncology Institute, Lyon University Hospital, Lyon, France.
21
Department of Haematology, Strasbourg University Hospital, Strasbourg, France.
22
Haematology Department, Nancy University Hospital, Nancy, France.
23
Department of Haematology, Saint-Antoine Hospital, APHP, Paris, France.
24
Department of Haematology, Montpellier University Hospital, Montpellier, France.
25
Henri Becquerel Centre, Rouen, France.
26
Department of Haematology, Amiens University Hospital, Amiens, France.
27
Department of Paediatric Haematology, Lille University Hospital, Lille, France.
28
Pediatric Haematology Department, Bordeaux University Hospital, Bordeaux, France.
29
Department of Haematology, Necker Hospital, APHP, Paris, France.
30
Department of Haematology, Saint-Louis Hospital, APHP, Paris, France.
31
Department of Haematology, Liège University Hospital, Liège, Belgium.
32
Department of Haematology, Catholic University of Leuven, Leuven, Belgium.
33
Department of Haematology, Paoli-Calmettes Institute, Marseille, France.
34
CHRU Lille, Pôle Spécialités Médicales et Gérontologie (Medical Specialities and Gerontology), Service des Maladies du Sang (Department of Haematology), Secteur Allogreffe de Cellules Souches Hématopoïétiques (Allogeneic Stem Cell Transplantation Department), F59037, Lille, France. ibrahim.yakoubagha@chru-lille.fr.
35
Université de Lille (Lille University), UFR Médecine F59000, Lille, France. ibrahim.yakoubagha@chru-lille.fr.
36
LIRIC INSERM U995, 59000, Lille, France. ibrahim.yakoubagha@chru-lille.fr.

Abstract

The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. Given the lack of data comparing these two types of donor in the setting of non-myeloablative (NMA) or reduced-intensity (RIC) allo-HCT, we performed a multicentre retrospective study using graft-vs.-host disease-free relapse-free survival (GRFS) as our primary endpoint. We analysed the data of 151 consecutive HL patients who underwent NMA or RIC allo-HCT from a HAPLO (N  =  61) or MRD (N  =  90) between January 2011 and January 2016. GRFS was defined as the probability of being alive without evidence of relapse, grade 3-4 acute GVHD or chronic GVHD. In multivariable analysis, MRD donors were independently associated with lower GRFS compared to HAPLO donors (HR  =  2.95, P   < 0.001). Disease status at transplant other than CR was also associated with lower GRFS in multivariable analysis (HR  =  1.74, P  =  0.01). In addition, the administration of ATG was independently linked to higher GRFS (HR  =  0.52, P  =  0.009). In summary, we observed significantly higher GRFS in HL patients receiving an allo-HCT using the HAPLO PT-Cy platform compared to MRD.

PMID:
29330405
DOI:
10.1038/s41409-017-0018-z
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for ORBi (University of Liege)
Loading ...
Support Center